MedDataX Logo

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

NCT ID: NCT00003827

Last Updated: 2013-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

1999-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.

PURPOSE: Phase II trial to study the effectiveness of combining topotecan and cytarabine given with amifostine in treating patients who have myelodysplastic syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine the toxic effects of amifostine, topotecan, and cytarabine in patients with poor risk myelodysplastic syndrome.
* Determine the hematologic response rate, cytogenetic response rate, and the rate of polyclonal hematopoiesis following this treatment regimen.
* Determine the duration of response and time to disease progression following this treatment regimen in these patients.

OUTLINE: Patients receive topotecan by continuous IV over 24 hours plus cytarabine IV over 2 hours, on days 1-5. Patients receive amifostine IV over 15 minutes every other day for a maximum of 60 days. Patients may receive a second course of the same regimen 8 weeks after the first.

Patients are followed at least monthly for 2 years, then every 3-6 months until death.

PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study within 1 to 1.5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia Myelodysplastic Syndromes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

refractory anemia with excess blasts refractory anemia with excess blasts in transformation de novo myelodysplastic syndromes secondary myelodysplastic syndromes childhood myelodysplastic syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

amifostine trihydrate

Intervention Type DRUG

cytarabine

Intervention Type DRUG

topotecan hydrochloride

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed poor risk myelodysplastic syndrome, including at least one of the following:

* Bilineage cytopenia
* Unfavorable cytogenetic abnormalities
* Refractory anemia with excess blasts and/or refractory anemia with excess blast in transformation (greater than 5% blast)
* At least 0.5 on the International Prognostic Score System
* No chronic myelomonocytic leukemia
* No hypocellular myelodysplastic syndrome (marrow cellularity less than 30%)

PATIENT CHARACTERISTICS:

Age:

* 16 and over

Performance status:

* ECOG 0-1

Life expectancy:

* Not specified

Hematopoietic:

* Absolute neutrophil count less than 1,500/mm3
* Platelet count less than 100,000/mm3
* Hemoglobin less than 10 g/dL

Hepatic:

* ALT less than 5 times upper limit of normal

Renal:

* Creatinine no greater than 1.4 mg/dL

Cardiovascular:

* No congestive heart failure

Other:

* Not pregnant or nursing
* Fertile patients must use effective contraception
* Must have right atrial catheter inserted

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* No prior blood or bone marrow transplantations

Chemotherapy:

* No prior acute myeloid leukemia chemotherapy (except hydroxyurea or low dose cytarabine)
* No prior topotecan
* No prior amifostine

Endocrine therapy:

* Not specified

Radiotherapy:

* Not specified

Surgery:

* Not specified

Other:

* At least 24 hours since prior antihypertensive medication prior to amifostine
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ALZA

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Henry C. Fung, MD, FRCPE

Role: STUDY_CHAIR

City of Hope Comprehensive Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cancer Center and Beckman Research Institute, City of Hope

Duarte, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHNMC-IRB-98056

Identifier Type: -

Identifier Source: secondary_id

ALZA-CHNMC-IRB-98056

Identifier Type: -

Identifier Source: secondary_id

NCI-V99-1533

Identifier Type: -

Identifier Source: secondary_id

CDR0000066982

Identifier Type: -

Identifier Source: org_study_id